公开(公告)号：US12151030B2

公开(公告)日：2024-11-26

申请号：US17426796

申请日：2020-01-30

Applicant: HISAMITSU PHARMACEUTICAL CO., INC.

Inventor： Takao Kurokawa ,  Hidekazu Kuma ,  Masaki Yukuhiro

IPC: A61K9/70 ,  A61K31/13 ,  A61K31/27 ,  A61K31/381 ,  A61K31/403 ,  A61K31/407 ,  A61K31/4422 ,  A61K31/573

Abstract: The present invention provides a patch comprising an adhesive layer on a backing, wherein the adhesive layer contains a adhesive base, a skin irritant drug or a pharmaceutically acceptable salt thereof, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0009 to 0.08% by mass based on the total mass of the adhesive layer.

公开(公告)号：US11033511B2

公开(公告)日：2021-06-15

申请号：US16610955

申请日：2018-07-30

Applicant: HISAMITSU PHARMACEUTICAL CO., INC.

Inventor： Akira Shuto ,  Takao Kurokawa ,  Junya Horiuchi ,  Hidekazu Kuma ,  Satoshi Amano

IPC: A61K9/70 ,  A61K31/216

Abstract: The present invention provides a patch comprising a backing, and an adhesive layer on the backing, wherein the adhesive layer contains at least one drug selected from the group consisting of oxybutynin and a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive base, and diflucortolone valerate, and the content of the diflucortolone valerate is 0.0007 to 0.05% by mass based on the total mass of the adhesive layer.

公开(公告)号：US20140271796A1

公开(公告)日：2014-09-18

申请号：US14354151

申请日：2012-10-23

Applicant: HISAMITSU PHARMACEUTICAL CO., INC.

Inventor： Kenji Atarashi ,  Kazuhiro Suzuki ,  Akio Takeuchi ,  Hidekazu Kuma

IPC: A61K31/575 ,  A61K31/235 ,  A61K9/70

CPC classification number: A61K31/575 ,  A61F2013/00646 ,  A61F2013/00906 ,  A61K9/0014 ,  A61K9/7023 ,  A61K9/7038 ,  A61K9/7053 ,  A61K9/7061 ,  A61K9/7084 ,  A61K9/7092 ,  A61K31/216 ,  A61K31/235 ,  A61K36/00 ,  A61K47/28 ,  A61K2300/00

Abstract: A transdermal absorption preparation containing at least one drug selected from oxybutynin and pharmaceutically acceptable salts thereof and 0.05% by mass or more of a sterol selected from cholesterols, cholesterol derivatives and cholesterol analogs, relative to a total amount of the transdermal absorption preparation.

Abstract translation: 相对于经皮吸收制剂的总量，含有选自奥昔布宁及其药学上可接受的盐中的至少一种药物和0.05质量％以上选自胆固醇，胆固醇衍生物和胆固醇类似物的固醇的透皮吸收制剂。